The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis
Open accessAbstract
Tumor necrosis factor-α (TNF-α) may contribute to the progression of acute alcoholic hepatitis (AAH). The aim of this study was to evaluate the efficacy of an association of infliximab and prednisolone at reducing the 2-month mortality rate among patients with severe AAH. Patients with severe AAH (Maddrey score ≥32) were randomly assigned to group A receiving intravenous infusions of infliximab (10 mg/kg) in weeks 0, 2, and 4; or group B receiving a placebo at the same times. All patients received prednisolone (40 mg/day) for 28 days. Blood neutrophil functional capacities were monitored over 28 days. After randomization of 36 patients, seven patients from group A and three from group B died within 2 months. The probability of being dead at 2 months was higher (not significant [NS]) in group A (39% ± 11%) than in group B (18% ± 9%). The study was stopped by the follow-up committee and the sponsor (Assistance Publique-Hôpitaux de Paris). The frequency of severe infections within 2 months was higher in group A than in group B (P < .002). This difference was potentially related to a significantly lower ex vivo stimulation capacity of neutrophils. There were no differences between the two groups in terms of Maddrey scores at any time point. In conclusion, three infusions of 10 mg/kg of infliximab in association with prednisolone may be harmful in patients with severe AAH because of the high prevalence of severe infections. (Hepatology 2004;39:1390-1397.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Cytokines in Alcoholic and Nonalcoholic Steatohepatitis
Tilg, H., & Diehl, A. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432007 · Cited by 948
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Khoruts, A., Stahnke, L., McClain, C. J., Logan, G., & Allen, J. I. (1991) · Hepatology · doi:10.1002/hep.1840130211 · Cited by 550
Carithers, R. L., Herlong, H. F., Diehl, A. M., Shaw, E. W., Combes, B., Fallon, H. J., & Maddrey, W. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-9-685 · Cited by 504
Iimuro, Y., Gallucci, R. M., Luster, M. I., Kono, H., & Thurman, R. G. (1997) · Hepatology · doi:10.1002/hep.510260621 · Cited by 497
Sandborn, W. J., & Hanauer, S. B. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00008 · Cited by 454
Mathurin, P., Mendenhall, C. L., Carithers, R. L., Ramond, M.-J., Maddrey, W. C., Garstide, P., Rueff, B., Naveau, S., Chaput, J.-C., & Poynard, T. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00289-6 · Cited by 353
Self-citationSerious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
(1964) · The Lancet · doi:10.1016/s0140-6736(64)91529-6 · Cited by 298
Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology
McCullough, A. (1998) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00468-7 · Cited by 271
Imperiale, T. F., & McCullough, A. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-4-299 · Cited by 232
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis
Tilg, H., Jalan, R., Kaser, A., Davies, N. A., Offner, F. A., Hodges, S. J., Ludwiczek, O., Shawcross, D., Zoller, H., Alisa, A., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00442-7 · Cited by 232
Spahr, L., Rubbia-Brandt, L., Frossard, J.-L., Giostra, E., Rougemont, A.-L., Pugin, J., Fischer, M., Egger, H., & Hadengue, A. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00230-1 · Cited by 214
Eissner, G., Kirchner, S., Lindner, H., Kolch, W., Janosch, P., Grell, M., Scheurich, P., Andreesen, R., & Holler, E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6193 · Cited by 193
Group Sequential Clinical Trials with Triangular Continuation Regions
Whitehead, J., & Stratton, I. (1983) · Biometrics · doi:10.2307/2530822 · Cited by 189
Dewas, C., Dang, P. M.-C., Gougerot-Pocidalo, M.-A., & El-Benna, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4392 · Cited by 163
Anti-cytokine therapeutics and infections
Dinarello, C. A. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00196-8 · Cited by 148
Taïeb, J., Mathurin, P., Elbim, C., Cluzel, P., Arce-Vicioso, M., Bernard‐Chabert, B., Opolon, P., Gougerot-Pocidalo, M. A., Poynard, T., & Chollet‐Martin, S. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80219-6 · Cited by 132
Self-citationA Unifying Family of Group Sequential Test Designs
Kittelson, J. M., & Emerson, S. S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00874.x · Cited by 98
Treatment of Alcoholic Hepatitis
O’Shea, R. S., & McCullough, A. J. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.11.004 · Cited by 55
[Corticoid therapy in the treatment of acute alcoholic hepatitis. Results of a meta-analysis].
Daurès, J. P., Fabbro-Péray, P., Bories, P., et al. (1991) · PubMed · Cited by 43
Nielsen, O. H., Brynskov, J., & Bendtzen, K. (1993) · PubMed · Cited by 30
Infliximab: A Review of its Use in Crohn??s Disease and Rheumatoid Arthritis
Onrust, S. V., & Lamb, H. M. (1998) · BioDrugs · doi:10.2165/00063030-199810050-00006 · Cited by 30
Nakada, M. T., Tam, S. H., Woulfe, D. S., Casper, K. A., Swerlick, R. A., & Ghrayeb, J. (1998) · Cell Communication & Adhesion · doi:10.3109/15419069809005606 · Cited by 24
Cited by
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
O'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Self-citationCrabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0805786 · Cited by 863
Self-citation
Metadata
- Authors
- Naveau, S., Chollet-Martin, S., Dharancy, S., Mathurin, P., Jouet, P., Piquet, M.-A., Davion, T., Oberti, F., Broët, P., & Emilie, D.
- Venue
- Hepatology
- Published
- 2004-05
- Volume
- 39
- Issue
- 5
- Pages
- 1390-1397
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2001288327
- Cited by
- 446
- References
- 29
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.